Toll-like receptors as therapeutic targets in gastrointestinal diseases

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 4, 2010, Pages 347-368

  Pimentel Nunes, Pedro ^a,b   Soares, João Bruno ^c   Roncon Albuquerque Jr , Roberto ^a   Dinis Ribeiro, Mário ^a,b   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c HOSPITAL DE BRAGA   (Portugal)

Author keywords

Gastrointestinal disease; Therapeutic targets; Therapy; Toll like receptors

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; CPG 10101; CPG OLIGODEOXYNUCLEOTIDE; CRX 526; ERITORAN; GASTROINTESTINAL AGENT; ISATORIBINE; PHENYLMETHIMAZOLE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2 ANTAGONIST; TOLL LIKE RECEPTOR 3 ANTAGONIST; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR 9 ANTAGONIST; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ALCOHOL LIVER DISEASE; BILIARY TRACT DISEASE; CELIAC DISEASE; CHRONIC PANCREATITIS; COLORECTAL CANCER; DRUG TARGETING; ENTERITIS; ENTEROPATHY; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER INJURY; LIVER ISCHEMIA; LIVER PERFUSION; NECROTIZING ENTEROCOLITIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; RADIATION INJURY; REVIEW; STOMACH ADENOCARCINOMA; SYSTEMATIC REVIEW;

ANIMALS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; TOLL-LIKE RECEPTORS;

EID: 77949547941     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003642027     Document Type: Review

References (288)

1. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85(2):85-95
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376
3. Barton GM, Medzhitov R. Control of adaptive immune responses by toll-like receptors. Curr Opin Immunol 2002;14(3):380-383
4. Napolitani G, Rinaldi A, Bertoni F, et al. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6(8):769-776
5. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499-511
6. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13(5):816-825
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
8. Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 2007;220:113-128
9. Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:60-81
10. Kaisho T, Akira S. Pleiotropic function of toll-like receptors. Microbes Infect 2004;6(15):1388-1394
11. Palazzo M, Gariboldi S, Zanobbio L, et al. Cross-talk among toll-like receptors and their ligands. Int Immunol 2008;20(5):709-718
12. Re F, Strominger JL. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004;173(12):7548-7555
13. Re F, Strominger JL. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology 2004;209(1-2):191-198
14. Hopkins PA, Sriskandan S. Mammalian toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005;140(3):395-407
15. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5(6):446-458
16. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol 2003;170(8):3977-3985
17. Abreu MT, Thomas LS, Arnold ET, et al. TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003;9(5):322-330
18. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167(3):1609-1616
19. Furrie E, MacFarlane S, Thomson G, MacFarlane GT. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005;115(4):565-574
20. Nomura F, Akashi S, Sakao Y, et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000;164(7):3476-3479
21. Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004;5(5):495-502
22. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006;7(2):148-155
23. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193(7):827-838
24. Gupta RA, Polk DB, Krishna U, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappaB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001;276(33):31059-31066
25. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5(1):104-112
26. Melmed G, Thomas LS, Lee N, et al. Human intestinal epithelial cells are broadly unresponsive to toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170(3):1406-1415
27. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004;126(4):1054-1070
28. Beutler BA. TLRs and innate immunity. Blood 2009;113(7):1399-1407
29. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann NY Acad Sci 2008;1143:21-34
30. Fukata M, Abreu MT. Role of toll-like receptors in gastrointestinal malignancies. Oncogene 2008;27(2):234-243
31. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009;87(2):125-138
32. Pasare C, Medzhitov R. Control of B-cell responses by toll-like receptors. Nature 2005;438(7066):364-368
33. Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 2007;44(12):3100-3111
34. Clyne M, Drumm B. Adherence of Helicobacter pylori to primary human gastrointestinal cells. Infect Immun 1993;61(10):4051-4057
35. Rad R, Brenner L, Krug A, et al. Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori. Gastroenterology 2007;133(1):150-163,e153
36. Smith MF Jr, Mitchell A, Li G, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappaB activation and chemokine expression by epithelial cells. J Biol Chem 2003;278(35):32552-32560
37. Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116(4):1092-1101
38. Mandell L, Moran AP, Cocchiarella A, et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004;72(11):6446-6454
39. Basak C, Pathak SK, Bhattacharyya A, et al. The secreted peptidyl prolyl cis, trans-isomerase HP0175 of Helicobacter pylori induces apoptosis of gastric epithelial cells in a TLR4- and apoptosis signal-regulating kinase 1-dependent manner. J Immunol 2005;174(9):5672-5680
40. Ishihara S, Rumi MA, Kadowaki Y, et al. Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol 2004;173(2):1406-1416
41. Kawahara T, Kuwano Y, Teshima-Kondo S, et al. Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection. J Med Invest 2001;48(3-4):190-197
42. Takenaka R, Yokota K, Ayada K, et al. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology 2004;150(Pt 12):3913-3922
43. Rad R, Ballhorn W, Voland P, et al. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 2009;136(7):2247-2257
44. Uno K, Kato K, Atsumi T, et al. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007;293(5):G1004-1012
45. Obonyo M, Sabet M, Cole SP, et al. Deficiencies of myeloid differentiation factor 88, toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect Immun 2007;75(5):2408-2414
46. Gobert AP, Bambou JC, Werts C, et al. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem 2004;279(1):245-250
47. Anderson AE, Worku ML, Khamri W, et al. TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol 2007;37(6):1548-1561
48. Torok AM, Bouton AH, Goldberg JB. Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun 2005;73(3):1523-1531
49. Lee SK, Stack A, Katzowitsch E, et al. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003;5(15):1345-1356
50. Andersen-Nissen E, Smith KD, Strobe KL, et al. Evasion of toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci USA 2005;102(26):9247- 9252
51. Gewirtz AT, Yu Y, Krishna US, et al. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;189(10):1914-1920
52. Schmausser B, Andrulis M, Endrich S, et al. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295(3):179-185
53. Hishida A, Matsuo K, Goto Y, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 2009;14(1):47-53
54. Trejo-De La OA, Torres J, Perez-Rodriguez M, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008;129(2):333-340
55. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007;68(11):901-907
56. Tahara T, Arisawa T, Wang F, et al. Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. Dig Dis Sci 2008;53(4):919-924
57. Inoue M, Sasazuki S, Wakai K, et al. Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. Gut 2009;58(10):1323-1332
58. Lee KM, Yeo M, Choue JS, et al. Protective mechanism of epigallocatechin-3-gallate against Helicobacter pylori-induced gastric epithelial cytotoxicity via the blockage of TLR-4 signaling. Helicobacter 2004;9(6):632-642
59. Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001;2(4):285-286
60. Chochi K, Ichikura T, Kinoshita M, et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 2008;14(10):2909-2917
61. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175(12):8242-8252
62. Chang YJ, Wu MS, Lin JT, et al. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol 2004;66(6):1465-1477
63. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007;67(9):4346-4352
64. Santini D, Angeletti S, Ruzzo A, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008;154(3):360-364
65. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007;132(3):905-912
66. Tahara T, Arisawa T, Wang F, et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007;98(11):1790-1794
67. Hietaranta A, Mustonen H, Puolakkainen P, et al. Proinflammatory effects of pancreatic elastase are mediated through TLR4 and NF-kappaB. Biochem Biophys Res Commun 2004;323(1):192-196
68. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168(10):5233-5239
69. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through toll-like receptor 4. J Immunol 2004;172(1):20-24
70. Song JM, Liu HX, Li Y, et al. Extracellular heat-shock protein 70 aggravates cerulein-induced pancreatitis through toll-like receptor-4 in mice. Chin Med J (Engl) 2008;121(15):1420-1425
71. Ding JL, Li Y, Zhou XY, et al. Potential role of the TLR4/IRAK-4 signaling pathway in the pathophysiology of acute pancreatitis in mice. Inflamm Res 2009;58(11):783-790
72. Sharif R, Dawra R, Wasiluk K, et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut 2009;58(6):813-819
73. Sawa H, Ueda T, Takeyama Y, et al. Role of toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg Today 2007;37(10):867-873
74. Peng Y, Sigua CA, Rideout D, Murr MM. Deletion of toll-like receptor-4 downregulates protein kinase C-z and attenuates liver injury in experimental pancreatitis. Surgery 2008;143(5):679-685
75. Zhang L, Wu HS, Chen Y, et al. Role of nitric oxide in toll-like receptor 2 and 4 mRNA expression in liver of acute hemorrhagic necrotizing pancreatitis rats. World J Gastroenterol 2006;12(3):485-488
76. Wu HS, Zhang L, Chen Y, et al. Effect of nitric oxide on toll-like receptor 2 and 4 gene expression in rats with acute lung injury complicated by acute hemorrhage necrotizing pancreatitis. Hepatobiliary Pancreat Dis Int 2005;4(4):609-613
77. Vonlaufen A, Xu Z, Daniel B, et al. Bacterial endotoxin: a trigger factor for alcoholic pancreatitis? Evidence from a novel, physiologically relevant animal model. Gastroenterology 2007;133(4):1293-1303
78. Pastor CM, Pugin J, Kwak B, et al. Role of toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. Crit Care Med 2004;32(8):1759-1763
79. Wang X, Wu L, Wu K, et al. Roles of endotoxin-related signaling molecules in the progression of acute necrotizing pancreatitis in mice. Pancreas 2005;31(3):251-257
80. Takagi Y, Masamune A, Kume K, et al. Microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene is associated with susceptibility to acute pancreatitis in Japan. Hum Immunol 2009;70(3):200-204
81. Zeng YJ, Song JM, Li Y, et al. Toll-like receptor 9 is expressed in rat pancreas and is involved in cerulein-induced pancreatitis. Pancreas 2008;36(2):212-214
82. Matsumura N, Takeyama Y, Ueda T, et al. Decreased expression of Toll-like receptor 2 and 4 on macrophages in experimental severe acute pancreatitis. Kobe J Med Sci 2007;53(5):219-227
83. Masamune A, Kikuta K, Watanabe T, et al. Pancreatic stellate cells express toll-like receptors. J Gastroenterol 2008;43(5):352-362
84. Soga Y, Komori H, Miyazaki T, et al. Toll-like receptor 3 signaling induces chronic pancreatitis through the Fas/Fas ligand-mediated cytotoxicity. Tohoku J Exp Med 2009;217(3):175-184
85. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of toll-like receptors on pancreatic islets. J Immunol 2004;172(5):3173-3180
86. Schwartz AL, Malgor R, Dickerson E, et al. Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 2009;15(12):4114-4122
87. Pratesi G, Petrangolini G, Tortoreto M, et al. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65(14):6388-6393
88. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53(3):355-361
89. Schmidt J, Welsch T, Jager D, et al. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007;97(5):598-604
90. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991;12(2):162-169
91. Parlesak A, Schafer C, Schutz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32(5):742-747
92. Adachi Y, Moore LE, Bradford BU, et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108(1):218-224
93. Hansen J, Cherwitz DL, Allen JI. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 1994;20(2):461-474
94. Carithers RL, McClain C. Alcoholic liver disease. In: Feldman L, Friedman L, Brandt J, editors, Sleisenger and fordtran's gastrointestinal and liver disease. Volume 2. 8 edition; 2006. p. 1771-1792
95. Uesugi T, Froh M, Arteel GE, et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001;34(1):101-108
96. Hritz I, Mandrekar P, Velayudham A, et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008;48(4):1224-1231
97. Seki E, Tsutsui H, Nakano H, et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 2001;166(4):2651-2657
98. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130(6):1886-1900
99. Uesugi T, Froh M, Arteel GE, et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002;168(6):2963-2969
100. Yin M, Bradford BU, Wheeler MD, et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001;166(7):4737-4742
101. Gustot T, Lemmers A, Moreno C, et al. Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006;43(5):989-1000
102. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007;102(7):1510-1517
103. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005;42(Suppl 1):S85-92
104. Nanji AA, Khwaja S, Tahan SR, Sadrzadeh SM. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J Pharmacol Exp Ther 1994;269(3):1280-1285
105. Valenti L, Ludovica Fracanzani A, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol 2009;31(3):359-369
106. Kawaratani H, Tsujimoto T, Kitazawa T, et al. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol 2008;14(43):6655-6661
107. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292(2):G518-525
108. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761-1772
109. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005;29(11 Suppl):140S-5S
110. Rivera CA, Adegboyega P, Van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47(4):571-579
111. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57(6):1470-1481
112. Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22(7):2416-2426
113. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37(2):343-350
114. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38(5):681-687
115. Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005;175(5):3165-3176
116. Chen Z, Cheng Y, Xu Y, et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128(3):400-408
117. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49(4):1132-1140
118. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45(1):102-110
119. Riordan SM, Skinner N, Kurtovic J, et al. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006;13(8):972-974
120. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74(5):2255-2264
121. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79(11):7269-7272
122. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46(6):1769-1778
123. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J Clin Immunol 2004;24(6):693-701
124. Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 2007;361(2):537-542
125. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005;23(45):5263-5270
126. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007;82(3):479-487
127. Dolganiuc A, Norkina O, Kodys K, et al. Viral and host factors induce macrophage activation and loss of Toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133(5):1627-1636
128. Dolganiuc A, Oak S, Kodys K, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004;127(5):1513-1524
129. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128(2):133-147
130. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5(3):215-229
131. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102(8):2992-2997
132. Otsuka M, Kato N, Moriyama M, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005;41(5):1004-1012
133. Abe T, Kaname Y, Hamamoto I, et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007;81(17):8953-8966
134. Miyazaki M, Kanto T, Inoue M, et al. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of toll-like receptors and retinoic acid inducible gene-I. J Med Virol 2008;80(6):980-988
135. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008;47(2):385-395
136. Yonkers NL, Rodriguez B, Milkovich KA, et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 2007;178(7):4436-4444
137. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006;80(2):866-874
138. Broering R, Wu J, Meng Z, et al. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914-922
139. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42(3):724-731
140. McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46(5):1341-1349
141. Chan CC, Hwang SJ, Lee FY, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997;32(9):942-946
142. Grinko I, Geerts A, Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J Hepatol 1995;23(4):449-458
143. Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22(2):165-172
144. Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol 1995;23(4):396-402
145. Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1318-1328
146. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13(11):1324-1332
147. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115(2):209-218
148. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37(5):1043-1055
149. Li Y, Chang M, Abar O, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009;51(4):750-757
150. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009;49(3):960-968
151. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007;46(2):297-306
152. Schnabl B, Brandl K, Fink M, et al. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008;375(2):210-214
153. Gabele E, Muhlbauer M, Dorn C, et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008;376(2):271-276
154. Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007;46(5):1509-1518
155. Lin CY, Tsai IF, Ho YP, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007;46(5):816-826
156. Testro AG, Gow PJ, Angus PW, et al. Effects of antibiotics on expression and function of toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol 2009: published online 19 November 2009, doi: 10.1016/j.jhep.2009.11.006
157. Pimentel-Nunes P, Roncon-Albuquerque R Jr, Gonçalves N, et al. Attenuation of toll-Like receptor 2 activation in alcoholic chronic liver disease: a mechanism for acquired immunodeficiency? Gastroenterology 2009;136(Suppl 5):A-451
158. Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003;37(5):1154-1164
159. Chen A, Zheng S. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol 2008;153(3):557-567
160. Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009;322(1-2):127-135
161. Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 2007;82(4):968-974
162. Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008;48(6):945-951
163. Rutenburg AM, Sonnenblick E, Koven I, et al. The role of intestinal bacteria in the development of dietary cirrhosis in rats. J Exp Med 1957;106(1):1-14
164. Liu X, Xu Q, Chen W, et al. Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of nonmethylated CpG DNA. Oncol Rep 2009;21(4):941-947
165. Yoneda K, Sugimoto K, Shiraki K, et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008;33(5):929-936
166. Khvalevsky E, Rivkin L, Rachmilewitz J, et al. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100(5):1301-1312
167. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16
168. Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002;139(4):234-243
169. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431-436
170. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48(2):380-381
171. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317(5834):121-124
172. Sakurai T, He G, Matsuzawa A, et al. Hepatocyte necrosis induced by oxidative stress and IL-1alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14(2):156-165
173. Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 2009;106(5):1548-1553
174. Wang AP, Migita K, Ito M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005;25(1):85-91
175. Shimoda S, Harada K, Niiro H, et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008;47(3):958-965
176. Takii Y, Nakamura M, Ito M, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005;85(7):908-920
177. Honda Y, Yamagiwa S, Matsuda Y, et al. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol 2007;47(3):404-411
178. Kikuchi K, Lian ZX, Kimura Y, et al. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 2005;24(4):347-352
179. Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27+ memory B cells in primary biliary cirrhosis. Gastroenterology 2005;128(2):304-312
180. Mao TK, Lian ZX, Selmi C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005;42(4):802-808
181. Harada K, Isse K, Kamihira T, et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 2005;41(6):1329-1338
182. Shen XD, Ke B, Zhai Y, et al. Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl 2007;13(10):1435-1443
183. Wang H, Li ZY, Wu HS, et al. Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway. Chin Med J (Engl) 2007;120(6):509-514
184. Zhai Y, Qiao B, Shen XD, et al. Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation 2008;85(7):1016-1022
185. Wu HS, Zhang JX, Wang L. Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2004;3(2):250-253
186. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004;173(12):7115-7119
187. Galloway E, Shin T, Huber N, et al. Activation of hepatocytes by extracellular heat shock protein 72. Am J Physiol Cell Physiol 2008;295(2):C514-520
188. Zhang JX, Wu HS, Wang H, et al. Protection against hepatic ischemia/ reperfusion injury via downregulation of toll-like receptor 2 expression by inhibition of Kupffer cell function. World J Gastroenterol 2005;11(28):4423-4426
189. Wang H, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol 2006;534(1-3):194-201
190. Yao XM, Chen H, Li Y. Protective effect of bicyclol on liver injury induced by hepatic warm ischemia/reperfusion in rats. Hepatol Res 2009;39(8):833-842
191. Jin X, Wang L, Wu HS, et al. N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2007;6(3):284-289
192. Testro AG, Visvanathan K, Angus PW, Gow PJ. Down-regulation of the toll-like receptor 4 dependent innate immune response protects against the development of acute allograft rejection in liver transplant recipients. J Gastroenterol Hepatol 2008;23(Suppl 4):A-251
193. Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009;119(2):305-314
194. Yohe HC, O'Hara KA, Hunt JA, et al. Involvement of toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1269-1279
195. Deng JF, Geng L, Qian YG, et al. The role of toll-like receptors 2 and 4 in acute allograft rejection after liver transplantation. Transplant Proc 2007;39(10):3222-3224
196. Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. Therapeutic approach to regulate innate immune response by toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol 2009;24(6):1089-1094
197. Thomas KE, Sapone A, Fasano A, Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 2006;176(4):2512-2521
198. Zanoni G, Navone R, Lunardi C, et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006;3(9):e358. Published online 19 September 2006, doi: 10.1371/journal.pmed.0030358 (Pubitemid 44455274)
199. Szebeni B, Veres G, Dezsofi A, et al. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr 2007;45(2):187-193
200. Kato S, Ito Y, Nishio H, et al. Increased susceptibility of small intestine to NSAID-provoked ulceration in rats with adjuvant-induced arthritis: involvement of enhanced expression of TLR4. Life Sci 2007;81(16):1309-1316
201. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008;57(2):181-187
202. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009;297(3):G506-513
203. Waselenko JK, Macvittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004;140(12):1037-1051
204. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320(5873):226-230
205. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004;127(1):224-238
206. Gibson DL, Ma C, Rosenberger CM, et al. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol 2008;10(2):388-403
207. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132(4):1359-1374
208. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009;137(1):209-220
209. Pierik M, Joossens S, Van Steen K, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006;12(1):1-8
210. Yang Z, Fuss IJ, Watanabe T, et al. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 2007;133(5):1510-1521
211. Watanabe T, Kitani A, Murray PJ, et al. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006;25(3):473-485
212. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122(7):1987-2000
213. Szebeni B, Veres G, Dezsofi A, et al. Increased expression of toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008;151(1):34-41
214. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006;103(18):7048-7053
215. Muratov V, Ulfgren AK, Engstrom M, et al. Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 2008;43(4):277-282
216. Heimesaat MM, Fischer A, Jahn HK, et al. Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 2007;56(7):941-948
217. Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One 2007;2(7):e662. Published online 25 July 2007, doi: 10.1371/journal.pone.0000662
218. Canto E, Ricart E, Monfort D, et al. TNFalpha production to TLR2 ligands in active IBD patients. Clin Immunol 2006;119(2):156-165
219. Arranz A, Abad C, Juarranz Y, et al. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann NY Acad Sci 2006;1070:129-134
220. Arranz A, Juarranz Y, Leceta J, et al. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 2008;29(6):948-956
221. Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288(5):G1055-1065
222. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118(2):229-241
223. Araki A, Kanai T, Ishikura T, et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005;40(1):16-23
224. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006;25(2):319-329
225. Matharu KS, Mizoguchi E, Cotoner CA, et al. Toll-like receptor 4-mediated regulation of spontaneous Helicobacter-dependent colitis in IL-10-deficient mice. Gastroenterology 2009;137(4):1380-1390
226. Fort MM, Mozaffarian A, Stover AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174(10):6416-6423
227. Teng X, Xu LF, Zhou P, et al. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation 2009;32(2):120-129
228. Tuin A, Poelstra K, De Jager-Krikken A, et al. Role of alkaline phosphatase in colitis in man and rats. Gut 2009;58(3):379-387
229. Lee JH, Lee B, Lee HS, et al. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int J Colorectal Dis 2009;24(2):231-237
230. Eun CS, Han DS, Lee SH, et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on toll-like receptor pathway. Dig Dis Sci 2006;51(4):693-697
231. Morimoto M, Watanabe T, Yamori M, et al. Isoflavones regulate innate immunity and inhibit experimental colitis. J Gastroenterol Hepatol 2009;24(6):1123-1129
232. Ungaro R, Fukata M, Hsu D, et al. A novel toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009;296(6):G1167-1179
233. Hume GE, Fowler EV, Doecke J, et al. Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflamm Bowel Dis 2008;14(5):585-590
234. Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007;102(11):2504-2512
235. De Jager PL, Franchimont D, Waliszewska A, et al. The role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007;8(5):387-397
236. Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/ NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005;11(5):681-685
237. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53(7):987-992
238. Ouburg S, Mallant-Hent R, Crusius JB, et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut 2005;54(3):439-440
239. Vijay-Kumar M, Wu H, Aitken J, et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007;13(7):856-864
240. Zhou R, Wei H, Sun R, Tian Z. Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. J Immunol 2007;178(7):4548-4556
241. Zhou R, Wei H, Sun R, et al. NKG2D recognition mediates toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc Natl Acad Sci USA 2007;104(18):7512-7515
242. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68(12):7010-7017
243. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167(4):1882-1885
244. Rhee SH, Im E, Riegler M, et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA 2005;102(38):13610-13615
245. Carvalho FA, Barnich N, Sauvanet P, et al. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis 2008;14(8):1051-1060
246. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113(9):1296-1306
247. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007;13(5):524-530
248. Gewirtz AT, Vijay-Kumar M, Brant SR, et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1157-1163
249. Vijay-Kumar M, Sanders CJ, Taylor RT, et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007;117(12):3909-3921
250. Steenholdt C, Andresen L, Pedersen G, et al. Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease. Scand J Gastroenterol 2009;44(2):195-204
251. Saruta M, Targan SR, Mei L, et al. High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females. Inflamm Bowel Dis 2009;15(3):321-327
252. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122(5):1428-1441
253. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005;115(3):695-702
254. Obermeier F, Strauch UG, Dunger N, et al. In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005;54(10):1428-1436
255. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126(2):520-528
256. Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann NY Acad Sci 2006;1072:351-355
257. Rachmilewitz D, Karmeli F, Shteingart S, et al. Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis 2006;12(5):339-345
258. Obermeier F, Dunger N, Deml L, et al. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002;32(7):2084-2092
259. Mane J, Pedrosa E, Loren V, et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. J Nutr 2009;139(3):603-610
260. Obermeier F, Dunger N, Strauch UG, et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005;129(3):913-927
261. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004;127(1):365-366
262. Torok HP, Glas J, Endres I, et al. Epistasis between toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009;104(7):1723-1733
263. Lee J, Mo JH, Katakura K, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8(12):1327-1336
264. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009;14(2):248-272
265. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451-459
266. Laqueur GL, Matsumoto H, Yamamoto RS. Comparison of the carcinogenicity of methylazoxymethanolbeta- D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J Natl Cancer Inst 1981;67(5):1053-1055
267. Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115(2):281-286
268. Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4(6):e6026. Published online 24 June 2009, doi: 10.1371/journal.pone. 0006026
269. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131(3):862-877
270. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133(6):1869-1881
271. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 2009, 29(7):2473-2478
272. Sun Q, Liu Q, Zheng Y, Cao X. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 2008;45(10):2929-2936
273. Sun Q, Zheng Y, Liu Q, Cao X. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. Int Immunopharmacol 2008;8(13-14):1854-1858
274. Earl TM, Nicoud IB, Pierce JM, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16(4):1043-1050
275. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65(12):5009-5014
276. Yoshioka T, Morimoto Y, Iwagaki H, et al. Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. J Int Med Res 2001;29(5):409-420
277. Boraska Jelavic T, Barisic M, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006;70(2):156-160
278. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008;135(2):518-528
279. Rayburn ER, Wang W, Zhang R, Wang H. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 2007;30(6):1511-1519
280. Kim HA, Ko HM, Ju HW, et al. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. Cancer Lett 2009;274(1):160-164
281. Damiano V, Caputo R, Garofalo S, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 2007;104(30):12468-12473
282. Damiano V, Caputo R, Bianco R, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006;12(2):577-583
283. Bertin S, Samson M, Pons C, et al. Comparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivo. Mol Cell Proteomics 2008;7(12):2311-2322
284. Jilling T, Simon D, Lu J, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol 2006;177(5):3273-3282
285. Qi W, Ebbert KV, Craig AW, et al. Absence of Fer protein tyrosine kinase exacerbates endotoxin induced intestinal epithelial barrier dysfunction in vivo. Gut 2005;54(8):1091-1097
286. Lu J, Jilling T, Li D, Caplan MS. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007;61(4):427-432
287. Leaphart CL, Cavallo J, Gribar SC, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol 2007;179(7):4808-4820
288. Gribar SC, Sodhi CP, Richardson WM, et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol 2009;182(1):636-46 Affiliation Pedro Pimentel-Nunes1,2, Joao Bruno Soares3, Roberto Roncon-Albuquerque Jr, Mário Dinis-Ribeiro2,4 & Adelino F Leite-Moreira†1 †Author for correspondence 1University of Porto, Department of Physiology, Cardiovascular Research & Development Unit, Faculty of Medicine, Al. Prof. Hernani Monteiro, 4200-319, Portugal Tel: +351 22 5513644; Fax: +351 22 5513646; E-mail: amoreira@med.up.pt 2Portuguese Oncology Institute, Gastroenterology Department, Porto, Portugal 3Hospital de S. Marcos, Gastroenterology Department, Braga, Portugal 4CINTESIS/Department of Biostatistics and Medical Informatics, Porto Faculty of Medicine, Porto, Portugal